Differential Effects of Selective Endothelin Type A Receptor Antagonist on the Gene Expression of Vascular Endothelial Growth Factor and Its Receptors in Streptozotocin-Induced Diabetic Heart

Abstract

Cardiovascular complications are an important feature of diabetes mellitus (DM). Abnormal and decreased coronary collateral development has been implicated in the pathogenesis of cardiac complications in DM. More recently, decreased expression of vascular endothelial growth factor (VEGF) and its receptors has been found in diabetic heart. To our knowledge, no study has focused on the therapeutic improvement associated with VEGF in diabetic heart. DM was induced by intraperitoneal injection of streptozotocin (65 mg/kg) in Sprague-Dawley rats, while control rats received only citrate buffer. After 1 week, the streptozotocin-treated rats were randomly divided into two groups: one group received the selective endothelin (ET) type A receptor antagonist TA-0201 at a dose of 1 mg/kg/day for 2 weeks by osmotic mini-pump, and the vehicle group received saline only. The plasma glucose level was 504 ± 75 mg/dl in the diabetic rats and was unchanged by treatment with ET antagonist. The body weight was decreased in the diabetic rats compared with the control rats, but the left ventricular (LV)–body weight ratio was increased in the diabetic group and was unaffected by treatment with ET antagonist. mRNA expression of VEGF and its receptors (Flt-1 and Flk-1) in the LV tissues was assessed using real-time polymerase chain reaction. VEGF expression was significantly decreased in diabetic heart and was greatly improved by treatment with ET antagonist. The expression of VEGF receptors was down-regulated in early diabetic heart but was not recovered by treatment with ET antagonist. ET and its receptor A might have differential regulation on the gene expressions of VEGF and its receptors in early diabetic heart.

Get full access to this article

View all access options for this article.

References

Sander GE, Giles TD. Diabetes mellitus and heart failure. Am Heart Hosp J 1:273–280, 2003.

Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC Jr, Sowers JR. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 100:1134–1146, 1999.

Heller GV. Evaluation of the patient with diabetes mellitus and suspected coronary artery disease. Am J Med 118(suppl 2):9S–14S, 2005.

Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 18:4–25, 1997.

Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306–1309, 1989.

Banai S, Shweiki D, Pinson A, Chandra M, Lazarovici G, Keshet E. Upregulation of vascular endothelial growth factor expression induced by myocardial ischemia: implications for coronary angiogenesis. Cardiovasc Res 28:1176–1179, 1994.

Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor and its receptors. FASEB J 13:9–22, 1999.

Shinohara K, Shinohara T, Mochizuki N, Mochizuki Y, Sawa H, Kohya T, Fujita M, Fujioka Y, Kitabatake A, Nagashima K. Expression of vascular endothelial growth factor in human myocardial infarction. Heart Vessels 11:113–122, 1996.

Abaci A, Oguzhan A, Kahraman S, Eryol NK, Unal S, Arinc H, Ergin A. Effect of diabetes mellitus on formation of coronary collateral vessel. Circulation 99:2239–2242, 1999.

10.

Aronson D, Rayfield EJ, Chesebro JH. Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction. Ann Intern Med 126: 296–306, 1997.

11.

Chou E, Suzuma I, Way KJ, Opland D, Clermont AC, Naruse K, Suzuma K, Bowling NL, Vlahos CJ, Aiello LP, King GL. Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic states: a possible explanation for impaired collateral formation in cardiac tissue. Circulation 105:373–379, 2002.

12.

Miyauchi T, Masaki T. Pathophysiology of endothelin in the cardiovascular system. Annu Rev Physiol 61:391–415, 1999.

13.

Cardillo C, Campia U, Bryant MB, Panza JA. Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation 106:1783–1787, 2002.

14.

Takeda Y, Miyamori I, Yoneda T, Takeda R. Production of endothelin-1 from the mesenteric artery of streptozotocin-induced diabetic rats. Life Sci 48:2553–2556, 1991.

15.

Makino A, Kamata K. Elevated plasma endothelin-1 level in streptozotocin-induced diabetic rats and responsiveness of the mesenteric arterial bed to endothelin-1. Br J Pharmacol 123:1065–1072, 1998.

16.

Hopfner RL, McNeill JR, Gopalakrishnan V. Plasma endothelin levels and vascular responses at different temporal stages of streptozotocin diabetes. Eur J Pharmacol 374:221–227, 1999.

17.

Donatelli M, Colletti I, Bucalo ML, Russo V, Verga S. Plasma endothelin levels in NIDDM patients with macroangiopathy. Diabetes Res 25:159–164, 1994.

18.

Morise T, Takeuchi Y, Kawano M, Koni I, Takeda R. Increased plasma levels of immunoreactive endothelin and von Willebrand factor in NIDDM patients. Diabetes Care 18:87–89, 1997.

19.

Anstadt MP, Hutchinson J, Portik-Dobos V, Jafri F, Bannan M, Mawulawde K, Ergul A. Vascular endothelin converting enzyme-1 expression and activity is upregulated in clinical diabetes. Ethn Dis 12:S3–S5–S9, 2002.

20.

Sasso FC, Carbonara O, Persico E, D’Ambrosio R, Coppola L, Nasti R, Campana B, Moschella S, Torella R, Cozzolino D. Increased vascular endothelial growth factor mRNA expression in the heart of streptozotocin-induced diabetic rats. Metabolism 52:675–678, 2003.

21.

Sabia PJ, Powers ER, Ragosta M, Sarembock IJ, Burwell LR, Kaul S. Association between collateral blood flow and myocardial viability in patients with recent myocardial infarction. N Engl J Med 327:1825–1831, 1992.

22.

Losordo DW, Dimmeler S. Therapeutic angiogenesis and vasculogenesis for ischemic disease: part II: cell-based therapies. Circulation 109:2692–2697, 2004.

23.

Losordo DW, Dimmeler S. Therapeutic angiogenesis and vasculogenesis for ischemic disease: part I: angiogenic cytokines. Circulation 109:2487–2491, 2004.

24.

Yoon YS, Uchida S, Masuo O, Cejna M, Park JS, Gwon HC, Kirchmair R, Bahlman F, Walter D, Curry C, Hanley A, Isner JM, Losordo DW. Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor. Circulation 111:2073–2085, 2005.

25.

Spinella F, Rosano L, Di Castro V, Natali PG, Bagnato A. Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1_α in ovarian carcinoma cells. J Biol Chem 277: 27850–27855, 2002.